ERBB2 and neoplasm: Interestingly, at low E/T ratio (1:1), a condition closer to the situation at the tumor site, HER2bsFab still remained significantly more potent than trastuzumab for inducing MCF-7 lysis, underlying the potential benefit of HER2bsFab against tumors expressing low HER2 levels in vivo.